Allied Health & Imaging · Independent exam preparation
ABMM Exam Free Study Guide and Practice Test Study Guide
A blueprint-aligned study guide for the American Board of Medical Microbiology examination, with 60 concepts, 20 original practice questions, and 20 flashcards.
By CertMedbry · Updated 13 October 2026
This guide uses the four domains and weights in the ASM-linked ABMM examination handbook. Its content outline is marked updated October 2023; no separate effective date is stated. The 60 concepts cover 26 testing, 11 administrative, 7 safety/security, and 16 consultation topics. This is a teaching allocation, not an official blueprint allocation. Scope note: The official ASM outline is the full examination scope. This guide selectively teaches major topics and does not cover every task in the outline; use the official outline as your completeness checklist. The practice questions and flashcards are independently authored learning materials, not official ABMM items or endorsed preparation.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
What is the official examination name, and what does DABMM mean?
ASM calls it the American Board of Medical Microbiology (ABMM) Exam. DABMM denotes diplomate status, not a separate examination.
American Board of Medical Microbiology (ABMM) · American Board of Medical Microbiology (ABMM) Exam
What question count and duration does the handbook state?
The handbook describes 200 multiple-choice questions, one correct answer per question, and six hours allowed. It does not state a scored-versus-pretest split, so do not infer one.
Which outline revision date is stated?
The handbook labels its content outline “UPDATED OCTOBER 2023.” It gives no separate effective date. Check ASM’s current exam-content link for updates.
American Board of Medical Microbiology (ABMM) Exam · ABMM Application Instructions
What are the official domain weights?
The handbook lists testing functions at 44.5%, administrative functions at 19%, safety and security at 11.5%, and consultation at 25%. Category percentages are portions of the whole examination, not percentages within each domain.
Are this guide’s questions official ABMM items or a pass predictor?
No. These are independently authored learning materials, not official ABMM questions or endorsed preparation. This short practice set is not a pass-prediction tool.
Does ABMM certification authorize laboratory direction everywhere?
No. ASM cautions that certification does not guarantee eligibility to direct a laboratory or practice medical microbiology in every jurisdiction. Local licensure and other requirements may apply.
American Board of Medical Microbiology (ABMM) · ABMM Application Instructions
ASM names the examination the American Board of Medical Microbiology (ABMM) Exam. DABMM denotes diplomate status, not a separate examination. The handbook describes a computer-based examination of 200 multiple-choice questions, one correct answer per question, and six hours allowed. ASM cautions that certification does not guarantee eligibility to direct a laboratory or practice in every jurisdiction.
Outline used: Current ASM-linked examination handbook retrieved 2026-10-11; content outline explicitly updated October 2023, pages 13–17. No separate effective date is stated. The workbook's Diplomate of the American Board of Medical Microbiology (DABMM) label maps to the ABMM examination leading to diplomate status; it is not a separate examination. Assigned slug preserved.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Directing Laboratory Testing Functions44.5%
1.How can specimen collection and transport change a result?
Collection site, volume, delay, temperature, and transport can affect detection or organism recovery. Assess specimen acceptance against method-specific requirements; qualify a result or request recollection when warranted. A completed assay is not necessarily dependable if the specimen was unsuitable. Exact requirements depend on assay and specimen type; the official outline includes collection and transport as influences on results.
Apply it
Compare a delayed specimen with validated stability limits before releasing a negative result. If limits were exceeded, discuss qualification or recollection with the care team.
Common pitfall: Do not assume that completing an assay makes an out-of-condition specimen reliable for interpretation.
2.How should testing distinguish TB infection from active disease?
An IGRA or tuberculin skin test indicates immune sensitization; it does not establish active pulmonary disease or identify viable bacilli. Active-disease evaluation may include acid-fast smear, nucleic acid amplification, and mycobacterial culture. These methods are complementary, and a negative smear does not rule out TB. Interpret results in light of the clinical question and specimen quality. CDC guidance supports this distinction.
Apply it
A patient with a positive infection test develops cough and abnormal imaging. Explain that the infection test is not an active-disease workup and discuss respiratory specimen testing.
Common pitfall: Do not substitute a positive TB infection assay for microbiologic evaluation when active disease is suspected.
3.Which identification clues should trigger confirmation and escalation for Candida auris?
Some identification systems may misidentify C. auris, and MALDI-TOF performance depends on suitable database coverage. Review the method’s validated capability and database version, and use an appropriate confirmation or referral pathway when needed. If C. auris is suspected, promptly contact local or state public health authorities and CDC for guidance; do not wait for confirmation before making that contact.
Apply it
A yeast from a high-risk setting receives an unexpected identification from an older database. Review the method’s coverage, arrange appropriate confirmation or referral, and promptly contact local or state public health authorities and CDC because C. auris is suspected.
Common pitfall: Do not treat an instrument’s confident species name or colony appearance as definitive, and do not delay public-health contact until a reference laboratory confirms the isolate.
Identification of C. auris · American Board of Medical Microbiology (ABMM) Exam
4.What does a negative Legionella urinary antigen leave unresolved?
The urinary antigen chiefly detects L. pneumophila serogroup 1. A negative result does not exclude other Legionella species or serogroups, or every infection caused by the target. Respiratory culture and molecular testing can broaden detection and answer different diagnostic questions. Interpret the result as evidence about the assay’s target, not universal exclusion; choose additional testing according to suspicion and specimen availability.
Apply it
A patient with severe pneumonia has a negative urinary antigen and a relevant exposure. Discuss respiratory culture or molecular testing rather than ending the investigation.
Common pitfall: Do not interpret a target-limited negative antigen result as comprehensive exclusion of Legionella infection.
5.When should malaria blood films be repeated after an initial negative result?
If malaria remains clinically suspected after an initial negative blood smear, repeat blood smears every 12–24 hours for a total of three sets before ruling out malaria, because low parasite density can make an early infection difficult to detect. Thick smears aid parasite detection; thin smears help identify species and quantify parasitemia. Communicate urgent positive findings promptly.
Apply it
A traveler with compatible symptoms has a negative first smear, but the clinical team remains concerned. Arrange repeat smears at 12–24-hour intervals until three sets have been examined, and promptly report any positive result.
Common pitfall: Do not rule out malaria on one negative smear when clinical suspicion persists. The three-set schedule applies in that situation; it is not an unconditional requirement for every negative smear.
6.Why can a negative rapid influenza antigen result mislead?
Rapid influenza diagnostic tests have limited sensitivity compared with molecular assays. Predictive value also depends on prevalence and setting, so a negative antigen result during substantial influenza activity may not exclude infection. Molecular testing may be appropriate when greater sensitivity is needed, including many hospitalized-patient situations. Communicate method limitations and follow current guidance for the patient and assay.
Apply it
A hospitalized patient with compatible illness has a negative antigen test during high influenza activity. Explain the sensitivity limitation and discuss molecular testing.
Common pitfall: Do not let a negative rapid antigen result override strong clinical suspicion without considering a more sensitive method.
Rapid Influenza Diagnostic Tests · Rapid Diagnostic Testing for Influenza: Information for Clinical Laboratory Directors
7.What does a positive C. difficile molecular result establish?
A nucleic acid test detects a genetic target associated with a toxigenic organism, not necessarily active toxin-mediated disease. Colonization can yield a positive result, so patient selection and context matter. Toxin detection may add information in multistep algorithms, but no assay removes the need for clinical interpretation. Stool handling matters because toxin can degrade; follow method-specific collection and stability requirements.
Apply it
A formed stool from a patient without compatible diarrhea is NAAT-positive. Discuss whether testing was appropriate and distinguish target detection from evidence of disease.
Common pitfall: Do not equate detection of a toxin gene with proof of toxin-mediated infection or a treatment indication.
8.Why can a resistance-gene result not replace phenotypic susceptibility testing?
Molecular resistance assays detect selected known determinants, whereas phenotypic testing measures growth response under defined conditions. A negative limited panel cannot exclude unrepresented mechanisms, and gene presence may not fully predict a clinical category. Molecular and phenotypic approaches can complement one another; rapid molecular findings may inform early decisions while phenotype provides broader information under validated interpretive criteria.
Apply it
An isolate is negative for genes on a rapid panel, but routine phenotype shows reduced susceptibility. Report the phenotype and investigate mechanisms outside the panel.
Common pitfall: Do not report susceptibility solely because a limited molecular panel did not detect its targeted genes.
Antimicrobial Resistance Laboratory Network Testing · American Board of Medical Microbiology (ABMM) Exam
9.How should unexpected findings from multiplex panels be handled?
Multiplex assays can produce findings outside the original clinical question or validated reportable menu. The outline calls attention to extraneous information and analytes that have not been verified. Define reportable targets, assess clinical relevance, and communicate limitations. Broad detection does not itself establish causality, active disease, or the appropriateness of reporting every generated signal. Apply the laboratory’s validated scope and reporting policy.
Apply it
A panel produces a signal outside the laboratory’s verified reporting scope. Check validation and reporting policy before releasing it as a patient result.
Common pitfall: Do not assume every instrument-generated signal is validated, clinically causal, or suitable for a clinical report.
10.What evidence supports changing a fungal identification workflow?
Evaluate a proposed method against the laboratory’s organisms, validated identification range, turnaround needs, and consequences of misidentification. Appraise studies by population, reference method, sample size, and discordant-result handling. For consequential fungi, database coverage and confirmation pathways matter. A new technology alone is not sufficient reason to change methods; the outline calls for evaluation of current practices and published evidence.
Apply it
Before replacing an identification method, compare performance for local isolates and define confirmation rules for organisms the new platform may not resolve.
Common pitfall: Do not infer clinical superiority from faster turnaround or a favorable manufacturer summary alone; assess evidence and intended use.
American Board of Medical Microbiology (ABMM) Exam · Identification of C. auris
11.How should parasitic diagnostic methods be matched to the clinical question?
Select a parasite test based on suspected organism, specimen, timing, and detection purpose. For suspected malaria, CDC guidance emphasizes timely blood-film evaluation and repeat films when suspicion remains despite an initial negative result. Other parasitic diagnoses require their own specimen and method choices. Do not assume one test or specimen addresses every parasite; the official outline includes current parasitic diagnostic practices.
Apply it
A clinician requests a malaria test after a negative first film. Explain the repeat-film approach and why testing must match the suspected parasite and clinical context.
Common pitfall: Do not generalize malaria microscopy guidance to every parasitic disease or regard a single negative test as universally conclusive.
Evaluation and Diagnosis of Malaria · American Board of Medical Microbiology (ABMM) Exam
12.How should bioinformatics findings affect sequence-result reporting?
A sequence signal is meaningful only within a validated pipeline, database, specimen context, and reporting policy. Define quality thresholds, contamination checks, reportable targets, and interpretive boundaries. The outline includes bioinformatics, analytics, sequencing, and management of findings that have not been verified. Results outside validated scope should not be presented as established diagnoses merely because a signal is detectable.
Apply it
A run yields a low-level organism signal alongside possible background contamination. Review controls, thresholds, and validation scope before assigning clinical significance.
Common pitfall: Do not treat sequence detection as proof of clinically significant infection or authorization to report an unvalidated finding.
13.What is the difference between analytical and clinical sensitivity?
Analytical sensitivity concerns the ability to detect low target amounts under defined conditions. Clinical sensitivity is the proportion of people with disease who test positive in the studied population. Clinical performance varies with disease stage, specimen, and case definition. A detection limit alone does not establish performance in a patient population; verification or validation must match intended use, as appropriate.
Apply it
An assay has a low analytical detection limit, but its clinical study excluded early disease. Explain why evidence relevant to the intended population is still needed.
Common pitfall: Do not claim strong clinical sensitivity from an analytical limit-of-detection study alone; the measures answer different questions.
American Board of Medical Microbiology (ABMM) Exam · Statistical Guidance on Reporting Results from Studies Evaluating Diagnostic Tests
14.How does prevalence affect positive predictive value?
Positive predictive value is true positives divided by all positive results. It depends on sensitivity, specificity, and prevalence. When prevalence falls, false positives can make up a larger share of positive results even if test characteristics remain unchanged. Predictive values cannot be transferred between populations without considering context and are distinct from sensitivity and specificity. The outline includes predictive-value calculations.
Apply it
With 90 true positives and 90 false positives, PPV is 90/(90+90), or 50%. Use the tested population’s prevalence when applying predictive values in practice.
Common pitfall: Do not assume high sensitivity alone makes a positive result highly predictive in a low-prevalence population.
American Board of Medical Microbiology (ABMM) Exam · Statistical Guidance on Reporting Results from Studies Evaluating Diagnostic Tests
15.What should verification establish before test-system use?
Verification establishes that a test performs as expected in the laboratory for its intended use; it is more than showing that an instrument runs. Address relevant performance characteristics, specimen types, precision, detection limits or reportable range as appropriate, and comparison with a suitable method. Requirements depend on assay and jurisdiction. Document a fit-for-purpose plan and acceptance criteria before releasing patient results.
Apply it
A laboratory introduces a molecular assay for a specimen type not previously used. Define performance checks and acceptance criteria before reporting patient results from that matrix.
Common pitfall: Do not assume manufacturer claims establish performance for every local specimen, workflow, or intended use.
16.How should specimen stability be included in a test protocol?
Stability studies assess whether a specimen retains acceptable performance under defined time, temperature, container, and handling conditions. They support transport and storage limits and help determine when to reject, qualify, or recollect. A claim applies only to tested specimen types and conditions; do not generalize it without evidence. The outline explicitly includes specimen stability in test development and verification.
Apply it
A clinic requests a longer shipping window. Compare proposed conditions with validated data and study them before extending the stability claim given to users.
Common pitfall: Do not transfer a stability claim from a different assay, matrix, container, or temperature without justification.
17.What is important when implementing a laboratory-developed test?
A laboratory-developed test is developed or implemented for a defined use, and its performance and limitations must be established under applicable requirements. The outline includes LDT development, validity, and verification. Regulatory obligations vary and may change, so consult current authoritative requirements. Documentation should define intended use, evidence, controls, limitations, and reporting language; publication alone does not establish local fitness for use.
Apply it
A laboratory adapts a published method to a new specimen matrix. Define intended use and establish local performance evidence and applicable oversight before clinical use.
Common pitfall: Do not confuse publication of a method with proof that a local implementation is fit for patient testing or compliant with current requirements.
18.How should published diagnostic studies be compared?
Compare intended population, specimen, disease definition, reference standard, execution, and handling of discordant or indeterminate results. Sensitivity and specificity may be biased if the reference standard incorporates the test or participants differ from local patients. Manufacturer data are evidence to appraise, not a substitute for independent evaluation. Ask whether the study answers the laboratory’s actual question.
Apply it
Two studies give different sensitivities; one includes only severe cases and the other includes early disease. Use their populations and case definitions to explain why estimates differ.
Common pitfall: Do not rank methods by one performance number without considering design, reference standard, and applicability.
Statistical Guidance on Reporting Results from Studies Evaluating Diagnostic Tests · American Board of Medical Microbiology (ABMM) Exam
19.Why can method agreement differ from diagnostic accuracy?
Agreement measures how often methods produce the same result; it does not establish which result is correct. Accuracy requires comparison with an appropriate reference framework, which may itself be imperfect. Two methods can agree because they share an error. Concordance is useful evidence, but its meaning depends on comparator quality, intended use, and discordant-result adjudication. Study design should consider incorporation bias.
Apply it
A candidate assay agrees with an existing method, but both use the same target and may miss a variant. Seek independent evidence before claiming accuracy.
Common pitfall: Do not present high agreement as proof of high clinical sensitivity or specificity without an appropriate reference and study design.
Statistical Guidance on Reporting Results from Studies Evaluating Diagnostic Tests
20.How should suspected molecular contamination be investigated?
A cluster of unexpected positives warrants review of preanalytical, analytical, and post-analytical pathways. Assess controls, extraction and amplification steps, reagent lots, workflow separation, specimen sequence, environmental conditions, and instrument records. Determine whether patient results are affected and contain risk before routine release if validity is uncertain. Document the cause, corrective action, and effectiveness assessment.
Apply it
Several low-level positives appear near a high-positive specimen. Review the run and workflow, define affected scope, and take documented action before releasing questionable results.
Common pitfall: Do not dismiss a pattern as random noise or repeat the run without examining shared causes and patient impact.
21.Which controls help establish whether a molecular run is valid?
Controls should challenge relevant steps and failure modes. Depending on the assay, they may include positive, negative, extraction, internal amplification, or process controls. A control that bypasses extraction cannot demonstrate extraction success. Choose materials and frequency appropriate to the method and applicable framework, with explicit acceptance criteria and actions. The outline highlights appropriate control material, matrices, and multiplex QC.
Apply it
A run has an amplification control but no extraction control. If extraction failure is a material risk, revise the strategy to assess that step appropriately.
Common pitfall: Do not assume one passing control verifies every preanalytical and analytical stage in a complex workflow.
American Board of Medical Microbiology (ABMM) Exam · 42 CFR 493.1256 — Standard: Control procedures
22.How should a laboratory investigate a susceptibility-testing nonconformity?
Review organism purity and identification, inoculum, medium, incubation, controls, method, and interpretive standard. Correct the process and assess whether previously released results are affected. Apply current breakpoints and document changes to methods or standards. The outline explicitly includes recognition of nonconformities and corrective action in antimicrobial and antifungal susceptibility testing; affected results may need reassessment under laboratory policy.
Apply it
A control strain falls outside its acceptable range. Hold affected results, check inoculum and conditions, investigate the cause, and verify acceptable performance before resuming reporting.
Common pitfall: Do not adjust a categorical result informally or report it using an outdated breakpoint system without an approved process.
American Board of Medical Microbiology (ABMM) Exam · EUCAST: Definitions of S, I and R
23.How should a laboratory director respond to an unexpected or discordant antifungal susceptibility result?
First establish that the result is analytically trustworthy: review isolate purity, inoculum preparation, method-specific conditions and endpoint, and quality-control acceptability. Investigate nonconformities and repeat testing from a pure isolate under the validated procedure when indicated. Interpret an MIC only with current, applicable organism–drug criteria; do not assign a susceptible or resistant category when no applicable clinical interpretive criterion exists. An in vitro result informs care but does not by itself guarantee a clinical outcome.
Apply it
A yeast isolate produces an unexpectedly high antifungal MIC while the run’s control is outside its acceptable range. Hold interpretation, investigate the control failure and testing conditions, and repeat as appropriate after corrective action. If a valid result still lacks an applicable clinical breakpoint, report its limitation rather than inventing a categorical interpretation.
Common pitfall: Do not compare MICs from different methods as if they were interchangeable, apply a generic breakpoint across organisms or drugs, or equate a single MIC with certain treatment success or failure.
24.How should malaria parasitemia be quantified on a thin blood smear?
Report the proportion of red blood cells infected, expressed as a percentage: infected RBCs divided by the total RBCs counted, multiplied by 100. Thin-smear microscopy allows parasite identification and quantification; interpret the result alongside species and the clinical picture.
Apply it
If 15 of 500 counted RBCs are infected, parasitemia is (15 ÷ 500) × 100 = 3%. Report and communicate the result according to the laboratory’s validated procedure.
Common pitfall: Do not confuse the RBC-based percentage with a parasite count using a white-cell denominator; use the calculation specified by the laboratory’s validated method.
25.How should a laboratory assess a new diagnostic method for an emerging infection?
Critically review evidence, intended use, target coverage, specimen requirements, performance, and limits before adopting or changing a workflow. The official outline calls for matching current practices to emerging infections and evaluating studies and new technologies. Rapid deployment may be important, but local validation, reporting boundaries, and communication remain necessary. Consult current guidance as evidence and epidemiology evolve.
Apply it
A new assay becomes available during an outbreak. Review evidence and local implementation requirements, then explain what the method can and cannot establish.
Common pitfall: Do not confuse urgency with permission to overstate a method’s validated scope or evidence base. Before implementation, define the validated intended use, reporting boundaries, and known limitations for the specific assay.
26.How should analytical specificity and cross-reactivity be considered when evaluating a diagnostic assay?
Assess whether the assay distinguishes its intended target from relevant related organisms or substances in the intended specimens. Cross-reactivity can produce misleading positives, while testing only a narrow set of potential interferents may leave uncertainty. Review study design, comparator methods, and intended-use population; document limitations and reporting language. Analytical specificity is not interchangeable with clinical specificity, which depends on performance in a defined patient population.
Apply it
A candidate assay has promising sensitivity but limited cross-reactivity data for locally common related organisms. Identify the evidence gap and address it before making a broader performance claim.
Common pitfall: Do not treat absence of observed cross-reactivity in a small or unrepresentative study as proof that clinically relevant interference is impossible.
Statistical Guidance on Reporting Results from Studies Evaluating Diagnostic Tests · American Board of Medical Microbiology (ABMM) Exam
Directing Laboratory Administrative Functions19%
27.How should a test menu reflect the population served?
A test menu should reflect disease prevalence, demographics, risk factors, specimen access, and the clinical decisions results can support. Age and care setting can change test value and interpretation. Review cost, utilization, turnaround, and alternatives with clinicians. The outline includes population impact, limitations, and diagnostic stewardship; revisit decisions when local needs or evidence change. A menu is a clinical and operational decision, not simply a list of available assays.
Apply it
A pediatric service frequently orders a test with limited interpretability in very young children. Review evidence with clinicians and consider a targeted ordering pathway.
Common pitfall: Do not assume a test useful for one patient group is automatically appropriate for every age or clinical setting.
American Board of Medical Microbiology (ABMM) Exam · Clinical Testing and Diagnosis for C. diff Infection
28.When does diagnostic stewardship justify changing an ordering pathway?
Stewardship is appropriate when testing is poorly matched to the clinical question, patient, specimen, or likely action. Interventions may include decision support, eligibility criteria, reflex rules, or consultation. Evaluate missed diagnoses, unnecessary testing, turnaround, and clinician workload. Use data and stakeholder input, then monitor unintended effects. Fewer orders alone do not demonstrate better stewardship.
Apply it
A service repeatedly orders tests with little expected incremental value. Review utilization and follow-up, implement a decision-support change with clinical partners, and monitor its effects.
Common pitfall: Do not equate fewer orders with better stewardship if the change delays or prevents necessary diagnosis.
29.How should turnaround time influence the test menu?
Turnaround matters when a result can change urgent treatment, isolation, or care. Balance speed with sensitivity, target coverage, specimen needs, and confirmation requirements. A rapid limited assay may answer one question but leave other causes unresolved. Agree on expectations and escalation with clinical partners; the outline asks directors to assess whether a test is critical and its turnaround appropriate. Consider validated alternatives and operational capacity.
Apply it
A time-sensitive assay is sent out despite a validated local method with a useful faster turnaround. Compare performance, availability, and clinical impact before changing routing.
Common pitfall: Do not substitute a faster, narrower test without explaining its target and limitations or considering the clinical question.
30.What is the appropriate response to failed quality control?
A failed control indicates that the affected run or test system may not meet acceptance criteria. Follow policy to stop release as indicated, define the scope of potentially affected results, investigate, and repeat or correct only when justified. Document the event, action, and effectiveness review. U.S. CLIA addresses control procedures and checks after certain major test-system changes; those requirements are jurisdiction-specific.
Apply it
A molecular negative control is positive. Hold affected results, investigate contamination and run scope, and establish acceptable system performance before release.
Common pitfall: Do not discard a failed control and release patient results merely because their signals appear plausible.
42 CFR 493.1256 — Standard: Control procedures · American Board of Medical Microbiology (ABMM) Exam
31.How can a control chart reveal a developing problem?
A control chart displays performance over time against defined limits and can reveal trends, shifts, or unusual patterns. A point may remain within a limit while a pattern merits review under local rules. Define action thresholds in advance and assess lots, operators, instruments, and process changes. Trend review complements immediate action on a failed control; it does not replace it. The outline includes Levey-Jennings charts and unusual-result patterns.
Apply it
Control values drift in one direction across several runs but remain in range. Review the pattern and process context before the assay produces an overt failure.
Common pitfall: Do not treat every in-range point as proof that a trending process is stable or needs no review whatsoever.
32.How does root-cause analysis differ from immediate correction?
Correction addresses the immediate problem; corrective action addresses its cause to reduce recurrence. Define the event and scope, examine contributing steps and evidence, select an action proportionate to risk, and monitor effectiveness. Avoid defaulting to retraining when equipment, workflow, environment, or system design may better explain the event. The outline expects root-cause analysis and effectiveness monitoring.
Apply it
Labeling errors recur on one shift. Correct affected records, investigate workflow and staffing factors, redesign as appropriate, and monitor recurrence.
Common pitfall: Do not close an event after a one-time recheck unless the cause is addressed and the action’s effectiveness is evaluated.
33.What immediate alert does U.S. CLIA require for critical results, and how should laboratories operationalize it?
Under 42 CFR § 493.1291(g), when a test result indicates an imminently life-threatening condition or a panic or alert value, the laboratory must immediately alert the individual or entity that requested the test and, if applicable, the individual responsible for using the test results. This is a U.S.-specific CLIA requirement. Local policy should operationalize the communication process—for example, by defining staff responsibilities, how the recipient is verified, escalation if the intended recipient cannot be reached, and how the alert is documented—without weakening the requirement to alert immediately.
Apply it
A result meets the laboratory’s critical-value criteria after the ordering clinician has left. Staff should immediately alert the requesting individual or entity and, if applicable, the person responsible for using the result, following the laboratory’s escalation procedure if the usual recipient is unavailable; document the communication according to policy.
Common pitfall: Do not describe the CLIA requirement as merely “prompt” notification or assume that releasing the result into an electronic record, without the required immediate alert, is sufficient. Local procedures guide how communication is carried out; they do not replace the federal requirement.
42 CFR 493.1291 — Standard: Test report · American Board of Medical Microbiology (ABMM) Exam
34.When should a corrected report be directly communicated?
A correction that could change diagnosis, treatment, infection control, or interpretation should be clearly identified and communicated through the laboratory’s process. Preserve an audit trail of the original result, correction, reason, time, and recipients. U.S. CLIA addresses identification of corrected reports and retention of the original report. Assess patient impact and ensure the correction reaches the responsible team.
Apply it
A confirmed identification revises a previously reported organism. Issue an identifiable corrected report and notify the care team if the change could affect management.
Common pitfall: Do not silently overwrite a report or assume that an electronic amendment was noticed by the original recipient.
35.How can contamination-rate data guide a quality intervention?
A useful rate has consistently defined numerator, denominator, period, and location. Stratifying blood-culture contamination can identify where focused improvement may be needed. Interpret changes alongside volume and case mix, because small denominators make rates unstable. CDC’s quality tool supports monitoring and location-specific feedback; the examination outline includes analysis of blood-culture contamination by unit.
Apply it
A unit has 12 contaminated sets among 200 collections: 12/200 equals 6%. Compare its consistently defined rate with other locations and target process review there.
Common pitfall: Do not compare percentages based on different definitions or ignore denominator size when deciding whether a change is meaningful.
Prevent Adult Blood Culture Contamination · Preventing Adult Blood Culture Contamination: A Quality Tool for Clinical Laboratory Professionals
36.How should a U.S. CLIA laboratory handle proficiency-testing samples?
Applicable U.S. CLIA proficiency-testing samples must be handled according to program rules and routine procedures. Some requirements prohibit interlaboratory communication or referral of PT material for analysis. Exact rules depend on analyte and program. Investigate unsatisfactory performance, identify affected processes, and document corrective action. PT is not a substitute for routine internal quality control or ongoing quality assessment.
Apply it
A staff member proposes sending a difficult PT sample to another laboratory. Check applicable CLIA rules and program instructions and use an allowed process instead.
Common pitfall: Do not handle regulated PT material as an ordinary patient specimen that can be referred or discussed without restriction.
Proficiency Testing Program Requirements: General & Cytology · American Board of Medical Microbiology (ABMM) Exam
37.What should happen when formal proficiency testing is unavailable?
When appropriate formal PT is unavailable, design a documented alternative assessment consistent with applicable rules and the quality system. A challenge may assess the testing process and should include review, discrepancy investigation, and corrective action. The outline expressly includes alternative PT; acceptable approaches depend on jurisdiction and test context. Routine control testing alone answers a different question.
Apply it
No suitable external program exists for a rare organism identification method. Create a documented challenge, define review criteria, and plan discrepancy follow-up.
Common pitfall: Do not call routine control testing proficiency testing or assume every alternative exchange is permitted under applicable rules.
American Board of Medical Microbiology (ABMM) Exam · Proficiency Testing Program Requirements: General & Cytology
Ensuring Safety and Security in the Laboratory11.5%
38.How can aerosol-generating work change a laboratory risk assessment?
Aerosol-generating procedures can increase exposure risk. Consider agent, specimen, procedure, equipment, containment, and work practices. Centrifugation, vigorous mixing, or opening containers may require controls such as sealed safety cups and appropriate containment. BMBL guidance is risk-assessment based and does not replace assessment of local activities. The outline expects recognition of aerosolization risks and suitable containment, PPE, and practices.
Apply it
A protocol adds vigorous mixing of a potentially infectious specimen. Reassess aerosol risk and specify controls before staff begin the revised procedure.
Common pitfall: Do not assign precautions from the organism name alone while ignoring the activity that may create exposure.
Biosafety in Microbiological and Biomedical Laboratories — 6th Edition · Biosafety in Microbiological and Biomedical Laboratories (BMBL) 6th Edition
39.When is a Class II biological safety cabinet an appropriate control?
A Class II biological safety cabinet can provide personnel, product, and environmental protection for appropriate microbiological work when correctly installed, certified, used, and maintained. Airflow may be disrupted by poor technique, clutter, or rapid movement. It is not general protection from chemical vapors. Select containment through task-specific assessment and follow current guidance and institutional procedures.
Apply it
A laboratory plans manipulations with possible infectious aerosols. Assess whether a certified cabinet and proposed work practices control the identified risks.
Common pitfall: Do not assume that placing work inside a cabinet ensures protection if technique or airflow is compromised.
Biosafety in Microbiological and Biomedical Laboratories — 6th Edition · Biosafety in Microbiological and Biomedical Laboratories (BMBL) 6th Edition
40.Why is alcohol not a substitute for a sporicidal disinfectant?
Alcohols are useful for some disinfection applications but are not sporicidal. Choose disinfectant activity to match the organism, surface, soil, contact time, and intended use, following product directions and institutional policy. CDC guidance distinguishes activity across disinfectant classes. Selection should be based on demonstrated efficacy rather than convenience or familiarity, particularly when spores are a concern.
Apply it
A spill involves material for which spores are a concern. Use an appropriate sporicidal product and contact time rather than routine alcohol wiping alone.
Common pitfall: Do not infer sporicidal activity from effectiveness against vegetative bacteria or from a general label as a disinfectant.
41.How should a laboratory select containment practices?
Use documented risk assessment that considers agent, volume, concentration, procedure, exposure route, facility, and personnel competency. Biosafety levels are not automatic labels for every organism and activity; work practices, engineering controls, PPE, and facilities interact. BMBL provides risk-assessment guidance. Consult current institutional and public-health requirements when a threat or activity presents unusual risk.
Apply it
A procedure begins aerosolizing concentrated material from a known organism. Reassess the activity and controls rather than relying only on the prior workflow’s containment designation.
Common pitfall: Do not assume an organism’s usual containment designation answers every procedure-specific safety question.
Biosafety in Microbiological and Biomedical Laboratories (BMBL) 6th Edition · Biosafety in Microbiological and Biomedical Laboratories — 6th Edition
42.What belongs in an emergency testing continuity plan?
A continuity plan identifies essential tests, alternate methods or sites, staffing and supply dependencies, communication routes, and criteria for activating and ending contingency operations. Site-specific assessment matters because power, transport, information systems, and staffing vulnerabilities differ. Understand limitations of alternatives and assign responsibilities. The outline includes emergency response, alternate protocols, and continuity of operations; review the plan periodically.
Apply it
An instrument failure interrupts urgent respiratory testing. Activate the documented alternate workflow, communicate changed turnaround and limitations, and track pending specimens.
Common pitfall: Do not improvise a substitute method without considering validation, biosafety, staffing, and clinical interpretation.
American Board of Medical Microbiology (ABMM) Exam · Biosafety in Microbiological and Biomedical Laboratories (BMBL) 6th Edition
43.What should guide response after a possible laboratory exposure?
Follow the institution’s exposure-response plan promptly: obtain appropriate assessment, document the event, identify material and route, and arrange indicated testing, prophylaxis, or follow-up. Response is agent- and exposure-specific and should involve occupational health and biosafety expertise. Review the event for contributing factors and prevention opportunities. Do not delay care while attempting a root-cause investigation.
Apply it
A staff member reports a splash to mucous membranes. Initiate the established immediate exposure pathway, notify designated experts, and document details for follow-up review.
Common pitfall: Do not apply a generic post-exposure regimen without considering agent, route, timing, and current clinical recommendations.
Biosafety in Microbiological and Biomedical Laboratories (BMBL) 6th Edition · American Board of Medical Microbiology (ABMM) Exam
44.How is biosecurity different from biosafety in a microbiology laboratory?
Biosafety focuses on preventing accidental exposure or release through risk assessment, containment, and safe work practices. Biosecurity focuses on protecting biological materials and related information from loss, theft, unauthorized access, or misuse. Develop and follow institutional biosecurity SOPs, restrict access appropriately, and consult current applicable regulatory guidance for select agents, bioterrorism concerns, or pandemic threats. Specific requirements depend on the material and jurisdiction.
Apply it
A laboratory’s biosafety assessment addresses aerosol containment, but access to high-consequence materials is uncontrolled. Address access, accountability, and security procedures separately under current institutional and applicable requirements.
Common pitfall: Do not assume PPE and containment alone satisfy biosecurity, or that an access-control plan replaces biosafety risk assessment.
American Board of Medical Microbiology (ABMM) Exam · Biosafety in Microbiological and Biomedical Laboratories (BMBL) 6th Edition
Consulting with Other Medical Professionals25%
45.How should blood-culture results be interpreted when contamination is possible?
Consider organism, positive sets and bottles, collection circumstances, time to positivity, and patient context. A skin-associated organism may represent contamination or true infection; species alone does not decide. Collection quality and blood volume affect yield and contamination. Communicate uncertainty and relevant patterns so clinicians can integrate results with the clinical picture and other tests. CDC emphasizes collection practices and monitoring.
Apply it
One of several sets grows a skin-associated organism in a patient without a device history. Share the pattern and collection details rather than labeling it automatically.
Common pitfall: Do not classify every skin-associated isolate as contamination or every positive bottle as bloodstream infection without context.
Prevent Adult Blood Culture Contamination · Preventing Adult Blood Culture Contamination: A Quality Tool for Clinical Laboratory Professionals
46.How should CSF microbiology be interpreted alongside other findings?
Interpret CSF culture or molecular findings with specimen quality, cell count, glucose, protein, stains, clinical presentation, and external testing. Antimicrobial exposure may reduce culture yield, while a detected organism requires assessment against syndrome and method. The outline expects integration of CSF culture with chemistry, hematology, and genetic testing. Distinguish direct evidence from supportive or conflicting findings.
Apply it
CSF culture is negative after antimicrobial treatment, but cell count and chemistry remain concerning. Explain the treatment limitation and discuss what additional evidence could help.
Common pitfall: Do not interpret one negative CSF result in isolation when prior therapy and other findings affect its meaning.
47.Which hepatitis B serology pattern is consistent with vaccine-derived immunity?
Negative HBsAg, negative total anti-HBc, and positive anti-HBs is consistent with vaccine-associated immunity: vaccination produces surface antibody, not core antibody. Resolved natural infection typically includes core antibody. Interpret the full panel with clinical history; unusual patterns may need follow-up. A single surface-antibody result should not replace review of other markers and history. Use current guidance when explaining the pattern.
Apply it
A vaccinated patient has negative HBsAg and anti-HBc with positive anti-HBs. Explain why the complete pattern supports vaccine-derived immunity rather than prior natural infection.
Common pitfall: Do not call positive surface antibody proof of resolved natural infection without considering total core antibody and history.
48.How should a discordant reverse-sequence syphilis screen be interpreted?
An initial reactive treponemal test with a nonreactive nontreponemal test calls for interpretation under the full algorithm; a second treponemal method can help adjudicate discordance. Treponemal antibodies often persist after treatment, so reactivity alone does not establish active infection or treatment failure. Consider history, prior therapy, clinical findings, and the complete testing sequence. CDC’s 2024 recommendations address this pattern.
Apply it
A treponemal screen is reactive and RPR is nonreactive. Review history and use the algorithm’s second treponemal test rather than declaring active disease from the screen alone.
Common pitfall: Do not equate persistent treponemal reactivity with active disease or a need for retreatment without clinical and laboratory context.
CDC Laboratory Recommendations for Syphilis Testing, United States, 2024
49.When should HIV RNA testing be considered despite a negative screening result?
When acute HIV is suspected, an early screening result may be negative because markers have not reached detection thresholds. HIV RNA can help detect infection earlier; follow current guidance on repeat testing and interpretation. Exposure timing, assay type, and clinical context matter. Explain the window-period limitation rather than treating one early negative screen as final. CDC guidance supports RNA testing when acute infection is suspected.
Apply it
A patient with recent high-risk exposure and compatible illness has a negative screen. Discuss HIV RNA testing and follow-up timing with the care team.
Common pitfall: Do not use an early negative screen to exclude infection when exposure timing and symptoms make the diagnostic window important.
50.How should a laboratory clarify specimen choice and timing after a negative Legionella urinary antigen?
First explain that the urinary antigen chiefly detects L. pneumophila serogroup 1. Then clarify whether a respiratory specimen is available, when it can be collected, and whether culture or molecular testing best addresses the remaining question. Respiratory testing may broaden detection. This consultation task coordinates specimen choice and timing and explains scope, rather than merely repeating the method limitation.
Apply it
A clinician asks whether a negative urinary antigen ended the evaluation. Explain its target, ask about respiratory specimen availability, and coordinate an appropriate complementary test if suspicion persists.
Common pitfall: Do not recommend an unspecified repeat test without clarifying specimen, timing, target, and the clinical question.
51.What does EUCAST “I” mean in a susceptibility discussion?
EUCAST defines I as susceptible, increased exposure: success is likely when exposure is increased by an appropriate regimen or concentration at the infection site. It is not simply an informal synonym for resistant or an unqualified susceptible category. Interpretation depends on current breakpoints, organism, agent, and exposure assumptions. Identify the system being used and communicate its meaning accurately to clinical partners.
Apply it
A pharmacist asks whether EUCAST I means resistance. Explain increased-exposure susceptibility and refer to the applicable breakpoint and regimen context.
Common pitfall: Do not translate EUCAST I automatically as resistant or assume it is interchangeable with another organization’s category.
52.How does an ECOFF differ from a clinical breakpoint?
An epidemiological cutoff value separates organisms without phenotypically detectable acquired resistance mechanisms from organisms with non-wild-type distributions. It does not by itself predict clinical success or failure. A clinical breakpoint incorporates clinical and pharmacological considerations for treatment interpretation. Do not use an ECOFF as a therapeutic breakpoint; use the relevant standard for its intended purpose.
Apply it
A report provides an ECOFF but no clinical breakpoint for a drug-organism pair. Explain that it can inform resistance surveillance but alone cannot establish a clinical susceptibility category.
Common pitfall: Do not use a surveillance cutoff as a treatment breakpoint without an authoritative clinical interpretation framework.
53.What information helps a pharmacist interpret antimicrobial susceptibility?
Interpretation depends on organism, drug, current breakpoint standard, infection site, route and achievable exposure, and relevant resistance mechanisms. A categorical result is not a universal guarantee of outcome. Clarify the method and interpretive standard and identify limitations. The outline includes drug classes, routes, resistance mechanisms, pharmacokinetic/pharmacodynamic data, and breakpoint guidance; patient-specific treatment decisions require broader clinical context.
Apply it
A pharmacist questions a category for a drug used at a site with different exposure assumptions. Discuss the breakpoint and current guidance rather than extrapolating from the label alone.
Common pitfall: Do not treat a reported category as independent of dose, route, infection site, or interpretive system.
EUCAST: Definitions of S, I and R · American Board of Medical Microbiology (ABMM) Exam
54.How can microbiology results support resistant-organism surveillance?
Surveillance requires consistent case definitions, reliable identification, and interpretable susceptibility data over time. Distinguish infection testing from colonization screening because they answer different questions and may use different workflows. Account for method changes, patient populations, and testing volume. Collaborate with infection preventionists on definitions, escalation criteria, and how findings should inform prevention actions.
Apply it
A facility compares resistant-organism counts before and after a screening-method change. Document the change and assess rates with consistent definitions before attributing trends to transmission.
Common pitfall: Do not interpret a rise in detected cases as increased transmission without considering changes in ascertainment and screening volume.
Antimicrobial Resistance Laboratory Network Testing · American Board of Medical Microbiology (ABMM) Exam
55.Which precautions are appropriate for suspected pulmonary tuberculosis?
CDC healthcare guidance recommends airborne precautions for suspected pulmonary or laryngeal TB, subject to stated criteria and local implementation. Distinguish suspected disease from a positive TB infection test alone, which does not establish contagious pulmonary disease. Coordinate placement and respiratory protection through institutional policy. Laboratory biosafety controls for specimens are related but separate, task-specific considerations.
Apply it
A patient with symptoms and imaging concerning for pulmonary TB awaits microbiology results. Advise the team to follow current airborne-precaution guidance while evaluation proceeds.
Common pitfall: Do not equate a positive latent-infection test alone with infectious pulmonary TB or wait for culture confirmation before acting on credible suspicion.
Appendix A: Type and Duration of Precautions Recommended for Selected Infections and Conditions · Clinical and Laboratory Diagnosis for Tuberculosis
56.How should a laboratory help infection prevention investigate a possible cluster?
Align laboratory results with timing, location, patient links, identification, and susceptibility or molecular data when appropriate. Check whether apparent similarity could reflect method changes, contamination, or inconsistent case definitions. The laboratory can support surveillance workflows and explain limitations, while infection prevention integrates epidemiology and exposure information. A single laboratory signal does not prove transmission without broader assessment.
Apply it
Several patients on one unit have similar resistant isolates. Verify testing consistency, share relevant timing and data, and support a structured epidemiologic review with infection prevention.
Common pitfall: Do not announce a transmission cluster based only on a shared broad species name or resistance label.
Antimicrobial Resistance Laboratory Network Testing · American Board of Medical Microbiology (ABMM) Exam
57.How should a director explain a research-use-only result to a clinician?
A research-use-only result is not automatically a validated patient-care result. Before communicating it for clinical decisions, consider whether the method is validated for that use, what applicable requirements permit, and how uncertainty will be described. The outline explicitly raises ethical communication of research-based tests. Be transparent about status and limitations, and discuss confirmatory clinical testing.
Apply it
A clinician requests an RUO result to guide treatment. Explain its status and limitations and discuss a validated alternative or appropriate confirmation.
Common pitfall: Do not present an unvalidated research result as an established clinical diagnosis merely because the finding is biologically plausible.
58.How can consultation about blood-culture contamination lead to a quality-improvement response?
After discussing an individual result pattern, work with clinical and collection teams to review collection circumstances, set definitions, examine location-specific rates, and agree on a targeted intervention. Monitor the same measure over time and provide feedback. This is a structured consultation and improvement task, distinct from deciding whether one patient’s isolate represents contamination. Interpret trends using consistent numerators, denominators, and collection processes.
Apply it
A unit’s consistently measured contamination rate is elevated. Share the data, review collection workflow with the unit, agree on an intervention, and monitor the rate and unintended effects.
Common pitfall: Do not label a unit or collector as the cause from a rate alone without validating definitions and reviewing the collection process.
Prevent Adult Blood Culture Contamination · Preventing Adult Blood Culture Contamination: A Quality Tool for Clinical Laboratory Professionals
59.How should a consultant communicate urgent malaria parasitemia findings?
Promptly communicate positive malaria microscopy findings through the laboratory’s urgent-result process, including species and quantified parasitemia when available and validated. Confirm receipt by the responsible clinical team and coordinate timely follow-up if the result is preliminary or additional review is needed. Repeat-film guidance for persistently suspected disease is a separate diagnostic decision; consultation focuses here on urgency, clarity, and closed-loop communication.
Apply it
A film shows malaria parasites and measurable parasitemia. Follow the urgent notification pathway, communicate the result and its status, confirm receipt, and coordinate any needed follow-up.
Common pitfall: Do not delay urgent notification while waiting for nonessential administrative completion or assume a routine electronic release ensures the clinical team saw it.
Evaluation and Diagnosis of Malaria · American Board of Medical Microbiology (ABMM) Exam
60.How should a consultant resolve a discordant influenza result pattern?
For a patient with compatible illness during substantial influenza activity, explain that a negative rapid antigen result does not exclude infection because sensitivity is limited. Clarify what the result supports and what remains unresolved, then discuss molecular testing when greater sensitivity is clinically needed. Incorporate specimen and timing, and communicate limitations without asserting influenza or an alternative diagnosis from the discordant pattern alone.
Apply it
A hospitalized patient has compatible symptoms and a negative antigen result during high influenza activity. Explain the test’s limitation and discuss whether molecular testing is justified for the clinical question.
Common pitfall: Do not call influenza excluded or confirmed from the antigen result alone when clinical context and method sensitivity make the result discordant.
Rapid Influenza Diagnostic Tests · Rapid Diagnostic Testing for Influenza: Information for Clinical Laboratory Directors
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Official domain weights: testing 44.5%, administrative 19%, safety/security 11.5%, and consultation 25%.
- The 60 teaching concepts cover 26 testing, 11 administrative, 7 safety/security, and 16 consultation topics. This editorial coverage allocation is not an official blueprint allocation.
- The 20 practice questions and 20-card set each use 9 testing, 4 administrative, 2 safety/security, and 5 consultation items, approximating official domain weights at this sample size.
- Within testing, practice fungal and parasitic diagnosis as well as bacterial, viral, mycobacterial, resistance, and method-evaluation decisions.
- The safety/security material distinguishes biosafety from biosecurity and directs learners to current applicable requirements and institutional SOPs.
- Category percentages in the handbook are percentages of the entire examination, not percentages within each domain.
- Practice interpreting specimen suitability, method limits, prevalence, verification, quality-control failures, and discordant results.
- Use current primary sources for evolving organisms, susceptibility interpretation, biosafety, and jurisdiction-specific requirements.
- These original drills are not official ABMM items, an adaptive simulation, or a pass-prediction tool.
A practical preparation plan
1. Anchor study to the official outline
Use the outline marked updated October 2023 and connect each task to a laboratory-director decision. The stated weights guide study allocation; category percentages refer to the whole examination.
2. Give testing functions appropriate emphasis
Testing is the largest domain. Cover bacterial, viral, fungal, mycobacterial, and parasitic diagnosis; specimen handling; susceptibility; method evaluation; and predictive values.
3. Study methods through their limits
For each method, ask what it detects, what it misses, what can invalidate it, what evidence supports use, and how to communicate uncertainty.
4. Distinguish biosafety and biosecurity
Assess accidental exposure and release risks through biosafety risk assessment and containment. Separately consider security of biological materials and related information, follow institutional biosecurity SOPs, and consult current applicable requirements.
5. Consult current primary sources
Use current CDC, EUCAST, CLIA, and biosafety sources for factual details. The outline is not a clinical guideline, and U.S. regulatory requirements are not universal.
6. Practice decisions across domains
Answer questions before reading explanations. Explain why distractors are weaker, then identify the transferable clue: specimen, population, method boundary, risk, or communication need.
7. Rehearse quality-event responses
Define scope, contain risk, investigate cause, correct the problem, and assess effectiveness. Separate immediate correction from action that prevents recurrence.
8. Keep credential and jurisdiction distinct
ASM names the examination the ABMM Exam; the DABMM label describes diplomate status. Verify current examination details and local licensure requirements independently.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- American Board of Medical Microbiology (ABMM)
- ABMM Application Instructions
- American Board of Medical Microbiology (ABMM) Exam
- Clinical and Laboratory Diagnosis for Tuberculosis
- Identification of C. auris
- Laboratory Testing for Legionella
- Evaluation and Diagnosis of Malaria
- Rapid Influenza Diagnostic Tests
- Rapid Diagnostic Testing for Influenza: Information for Clinical Laboratory Directors
- Clinical Testing and Diagnosis for C. diff Infection
- Antimicrobial Resistance Laboratory Network Testing
- Statistical Guidance on Reporting Results from Studies Evaluating Diagnostic Tests
- 42 CFR 493.1256 — Standard: Control procedures
- 42 CFR 493.1291 — Standard: Test report
- Proficiency Testing Program Requirements: General & Cytology
- Prevent Adult Blood Culture Contamination
- Preventing Adult Blood Culture Contamination: A Quality Tool for Clinical Laboratory Professionals
- Biosafety in Microbiological and Biomedical Laboratories (BMBL) 6th Edition
- Biosafety in Microbiological and Biomedical Laboratories — 6th Edition
- Chemical Disinfectants
- Clinical Testing and Diagnosis for Hepatitis B
- CDC Laboratory Recommendations for Syphilis Testing, United States, 2024
- HIV — STI Treatment Guidelines
- EUCAST: Definitions of S, I and R
- Appendix A: Type and Duration of Precautions Recommended for Selected Infections and Conditions
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.